{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:02:34Z","timestamp":1791050554530,"version":"4.1.0"},"reference-count":89,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.urolonc.2018.10.027","type":"journal-article","created":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T09:32:48Z","timestamp":1542965568000},"page":"763-773","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"title":["Mutations in renal cell carcinoma"],"prefix":"10.1016","volume":"38","author":[{"given":"Christopher","family":"D'Avella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Abbosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1712-0848","authenticated-orcid":false,"given":"Sumanta K.","family":"Pal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M.","family":"Geynisman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2018.10.027_bib0001","unstructured":"National Cancer I. Cancer of the kidney and renal pelvis \u2014cancer stat facts. 2016."},{"key":"10.1016\/j.urolonc.2018.10.027_bib0002","unstructured":"Moch HHPAUTMRVE. WHO classification of tumours of the urinary system and male genital organs. 2016. p. 400."},{"key":"10.1016\/j.urolonc.2018.10.027_bib0003","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/nrdp.2017.9","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0004","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1056\/NEJMra1601333","article-title":"Systemic therapy for metastatic renal-cell carcinoma","volume":"376","author":"Choueiri","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0005","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1053\/j.ackd.2013.10.001","article-title":"Hereditary kidney cancer syndromes","volume":"21","author":"Haas","year":"2014","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0006","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1158\/2159-8290.CD-14-1096","article-title":"Germline mutations in the CDKN2B tumor suppressor gene predispose to renal cell carcinoma","volume":"5","author":"Jafri","year":"2015","journal-title":"Cancer Discov"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0007","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1158\/1541-7786.MCR-13-0111","article-title":"A novel germline mutation in BAP1 predisposes to familial clear-cell renal cell carcinoma","volume":"11","author":"Farley","year":"2013","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0008","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1136\/jmedgenet-2014-102912","article-title":"A germline mutation in PBRM1 predisposes to renal cell carcinoma","volume":"52","author":"Benusiglio","year":"2015","journal-title":"J Med Genet"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0009","doi-asserted-by":"crossref","first-page":"804","DOI":"10.6004\/jnccn.2017.0100","article-title":"Kidney cancer, version 2.2017, NCCN clinical practice guidelines in oncology","volume":"15","author":"Motzer","year":"2017","journal-title":"J Natl Compr Cancer Netw"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0010","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1056\/NEJMoa1611406","article-title":"Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy","volume":"375","author":"Ravaud","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0011","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1016\/S0140-6736(16)00559-6","article-title":"Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial","volume":"387","author":"Haas","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0012","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.1200\/JCO.2017.73.5324","article-title":"Randomized phase III trial of adjuvant pazopanib vs. placebo after nephrectomy in patients with localized or locally advanced renal cell carcinoma","volume":"35","author":"Motzer","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0013","doi-asserted-by":"crossref","unstructured":"Posadas EM, Limvorasak S, Figlin RA. Targeted therapies for renal cell carcinoma. Nat Rev Nephrol. 2017;13. p. 496\u2013511.","DOI":"10.1038\/nrneph.2017.82"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0014","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1056\/NEJMoa1303989","article-title":"Pazopanib vs. Sunitinib in metastatic renal-cell carcinoma","volume":"369","author":"Motzer","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0015","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab vs. everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0016","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab vs. sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0017","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/S1470-2045(18)30081-0","article-title":"Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial","volume":"19","author":"Atkins","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0018","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1200\/JCO.2018.36.6_suppl.578","article-title":"IMmotion151: a randomized phase III study of atezolizumab plus bevacizumab vs sunitinib in untreated metastatic renal cell carcinoma (mRCC)","volume":"36","author":"Motzer","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0019","doi-asserted-by":"crossref","unstructured":"Clark PE, Cookson MS. The von Hippel-Lindau gene turning discovery into therapy. Cancer. 2008. p. 1768\u201378.","DOI":"10.1002\/cncr.23645"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0020","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1126\/science.8493574","article-title":"Identification of the von Hippel-Lindau disease tumor suppressor gene","volume":"260","author":"Latif","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0021","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1200\/JCO.2012.45.2003","article-title":"Molecular genetics of clear-cell renal cell carcinoma","volume":"32","author":"Brugarolas","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0022","doi-asserted-by":"crossref","unstructured":"Cowey CL, Rathmell WK. VHL gene mutations in renal cell carcinoma: Role role as a biomarker of disease outcome and drug efficacy. Curr Oncol Rep. 2009;11. p. 94\u2013101.","DOI":"10.1007\/s11912-009-0015-5"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0023","doi-asserted-by":"crossref","first-page":"5593","DOI":"10.1200\/JCO.2006.08.8948","article-title":"Molecular biology of renal cell cancer and the identification of therapeutic targets","volume":"24","author":"Iliopoulos","year":"2006","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0024","doi-asserted-by":"crossref","unstructured":"Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. The Lancet. 2009;373 p. 1119\u201332.","DOI":"10.1016\/S0140-6736(09)60229-4"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0025","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1200\/JCO.2017.74.2627","article-title":"Phase I Dose-Escalation trial of PT2385, a first-in-class hypoxia-inducible factor-2\u03b1 antagonist in patients with previously treated advanced clear cell renal cell carcinoma","volume":"36","author":"Courtney","year":"2017","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0026","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature19796","article-title":"Targeting renal cell carcinoma with a HIF-2 antagonist","volume":"539","author":"Chen","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0027","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/ng.2891","article-title":"Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing","volume":"46","author":"Gerlinger","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0028","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0029","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nature12222","article-title":"Comprehensive molecular characterization of clear cell renal cell carcinoma","volume":"499","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0030","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/PAP.0000000000000185","article-title":"Molecular and metabolic basis of clear cell carcinoma of the kidney","volume":"25","author":"Akhtar","year":"2018","journal-title":"Adv Anat Pathol"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0031","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nature12222","article-title":"Comprehensive molecular characterization of clear cell renal cell carcinoma","volume":"499","author":"Creighton","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0032","doi-asserted-by":"crossref","unstructured":"Fingar DC, Blenis J. Target of rapamycin (TOR): An an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 2004. p. 3151\u20133171.","DOI":"10.1038\/sj.onc.1207542"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0033","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/1097-0215(200002)9999:9999<::AID-IJC1034>3.0.CO;2-S","article-title":"PTEN\/MMAC1\/TEP1 mutations in human primary renal-cell carcinomas and renal carcinoma cell lines","volume":"91","author":"Kondo","year":"2001","journal-title":"Int J Cancer"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0034","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/ng.2699","article-title":"Integrated molecular analysis of clear-cell renal cell carcinoma","volume":"45","author":"Sato","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0035","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.eururo.2017.03.046","article-title":"Evolution of circulating tumor DNA Profile from first-line to subsequent therapy in metastatic renal cell carcinoma","volume":"72","author":"Pal","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12894-017-0209-3","article-title":"BAP1 and PBRM1 in metastatic clear cell renal cell carcinoma: tumor heterogeneity and concordance with paired primary tumor","volume":"17","author":"Eckel-Passow","year":"2017","journal-title":"BMC Urol"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0037","unstructured":"Turajilic, et al. Deterministic evolutionary trajectories influence primary tumor growth: TRACERx renal. Cell 2018;173:1\u201316."},{"key":"10.1016\/j.urolonc.2018.10.027_bib0038","unstructured":"Turajilic, et al. Tracking cancer evolution reveals constrained routes to metastases: TRACERx renal. Cell 2018;173:1\u201314."},{"key":"10.1016\/j.urolonc.2018.10.027_bib0039","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1200\/JCO.1998.16.6.2261","article-title":"Resection of metastatic renal cell carcinoma","volume":"16","author":"Kavolius","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0040","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.cell.2018.02.020","article-title":"Timing the landmark events in the evolution of clear cell renal cell cancer: TRACERx renal","volume":"173","author":"Mitchell","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0041","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1126\/science.1229259","article-title":"Highly recurrent TERT promoter mutations in human melanoma","volume":"339","author":"Huang","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0042","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1230062","article-title":"TERT promoter mutations in familial and sporadic melanoma","volume":"339","author":"Horn","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0043","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.cell.2011.12.013","article-title":"Genome sequencing of pediatric medulloblastoma links catastrophic DNA rearrangements with TP53 mutations","volume":"148","author":"Rausch","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0044","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cell.2010.11.055","article-title":"Massive genomic rearrangement acquired in a single catastrophic event during cancer development","volume":"144","author":"Stephens","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0045","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1146\/annurev.biochem.77.062706.153223","article-title":"The biology of chromatin remodeling complexes","volume":"78","author":"Clapier","year":"2009","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0046","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1158\/0008-5472.CAN-07-5276","article-title":"BAF180 is a critical regulator of p21 induction and a tumor suppressor mutated in breast cancer","volume":"68","author":"Xia","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0047","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1038\/s41467-017-02245-1","article-title":"Loss of PBRM1 rescues VHL dependent replication stress to promote renal carcinogenesis","volume":"8","author":"Espana-Agusti","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0048","doi-asserted-by":"crossref","first-page":"34179","DOI":"10.1074\/jbc.M109.046755","article-title":"The deubiquitinating enzyme BAP1 regulates cell growth via interaction with HCF-1","volume":"284","author":"Machida","year":"2009","journal-title":"J Biol Chem"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0049","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1128\/MCB.01517-08","article-title":"Association of C-terminal ubiquitin hydrolase BRCA1-associated protein 1 with cell cycle regulator host cell factor 1","volume":"29","author":"Misaghi","year":"2009","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0050","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1158\/0008-5472.CAN-17-2876","article-title":"Familial and somatic BAP1 mutations inactivate ASXL1\/2-mediated allosteric regulation of BAP1 deubiquitinase by targeting multiple independent domains","volume":"78","author":"Peng","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0051","doi-asserted-by":"crossref","first-page":"10292","DOI":"10.1038\/ncomms10292","article-title":"BAP1\/ASXL1 recruitment and activation for H2A deubiquitination","volume":"7","author":"Sahtoe","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0052","doi-asserted-by":"crossref","first-page":"3259","DOI":"10.1158\/1078-0432.CCR-12-3886","article-title":"Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network","volume":"19","author":"Hakimi","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0053","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/gcc.22116","article-title":"Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma","volume":"53","author":"Gossage","year":"2014","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0054","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S1470-2045(12)70584-3","article-title":"Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation","volume":"14","author":"Kapur","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0055","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1002\/ijc.27822","article-title":"Loss of PBRM1 expression is associated with renal cell carcinoma progression","volume":"132","author":"Pawlowski","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0056","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/nature09639","article-title":"Exome sequencing identifies frequent mutation of the SWI\/SNF complex gene PBRM1 in renal carcinoma","volume":"469","author":"Varela","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0057","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/ng.2323","article-title":"BAP1 loss defines a new class of renal cell carcinoma","volume":"44","author":"Pena-Llopis","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0058","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1002\/cncr.28521","article-title":"Loss of BAP1 protein expression is an independent marker of poor prognosis in patients with low-risk clear cell renal cell carcinoma","volume":"120","author":"Joseph","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0059","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/2159-8290.CD-17-1246","article-title":"An empirical approach leveraging tumorgrafts to dissect the tumor microenvironment in renal cell carcinoma identifies missing link to prognostic inflammatory factors","volume":"8","author":"Wang","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0060","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1200\/JCO.2018.36.6_suppl.639","article-title":"Incorporation of PBRM1, BAP1, TP53 mutation status into the Memorial Sloan Kettering Cancer Center (MSKCC) risk model: a genomically annotated tool to improve the stratification of patients with advanced renal cell carcinoma","volume":"36","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0061","doi-asserted-by":"crossref","unstructured":"Wagner EJ, Carpenter PB. Understanding the language of Lys36 methylation at histone H3. 2012;13 p. 115\u2013126.","DOI":"10.1038\/nrm3274"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0062","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1200\/JCO.2010.32.9110","article-title":"Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes","volume":"29","author":"Xu","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0063","first-page":"1","article-title":"Molecular subtypes of clear cell renal cell carcinoma are associated to sunitinib response in the metastatic setting","author":"Beuselinck","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0064","doi-asserted-by":"crossref","first-page":"25241","DOI":"10.18632\/oncotarget.8308","article-title":"Dynamic epigenetic changes to VHL occur with sunitinib in metastatic clear cell renal cancer","volume":"7","author":"Stewart","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0065","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/nm.3947","article-title":"Loss of BAP1 function leads to EZH2-dependent transformation","volume":"21","author":"LaFave","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0066","doi-asserted-by":"crossref","first-page":"4282","DOI":"10.1158\/0008-5472.CAN-13-3109","article-title":"Germline mutations in BAP1 impair its function in DNA double-strand break repair","volume":"74","author":"Ismail","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0067","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2016.10.007","article-title":"Genomic biomarkers of a randomized trial comparing first-line everolimus and sunitinib in patients with metastatic renal cell carcinoma","volume":"71","author":"Hsieh","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0068","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1158\/1078-0432.CCR-14-1128","article-title":"Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting","volume":"21","author":"Beuselinck","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0069","doi-asserted-by":"crossref","first-page":"820","DOI":"10.6004\/jnccn.2016.0086","article-title":"Whole-exome sequencing in two extreme phenotypes of response to vegf-targeted therapies in patients with metastatic clear cell renal cell carcinoma","volume":"14","author":"Fay","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0070","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1126\/science.aan5951","article-title":"Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma","volume":"359","author":"Miao","year":"2018","journal-title":"Science (New York, NY)"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0071","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/annonc\/mdv166","article-title":"Clinical usefulness of PI3K\/Akt\/mTOR genotyping in companion with other clinical variables in metastatic renal cell carcinoma patients treated with everolimus in the second and subsequent lines","volume":"26","author":"Bodnar","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0072","doi-asserted-by":"crossref","unstructured":"Ali SM, Stephens PJ, Miller VA, Ross JS, Pal SK. Selective response to mammalian target of rapamycin inhibition in a patient with metastatic renal cell carcinoma bearing TSC1 mutation. 2015;68 p. 341\u201343.","DOI":"10.1016\/j.eururo.2015.03.002"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0073","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1158\/1078-0432.CCR-13-2345","article-title":"Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy","volume":"20","author":"Voss","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0074","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1158\/1078-0432.CCR-15-2631","article-title":"Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic renal cell carcinoma","volume":"22","author":"Kwiatkowski","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0075","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.eururo.2017.05.033","article-title":"Characterization of clinical cases of advanced papillary renal cell carcinoma via comprehensive genomic profiling","volume":"73","author":"Pal","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0076","unstructured":"Srinivasan R. Translating evidence to multidisciplinary care. 2018 Genitourinary Cancers Symposium; 2018."},{"key":"10.1016\/j.urolonc.2018.10.027_bib0077","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1056\/NEJMoa1505917","article-title":"Comprehensive molecular characterization of papillary renal-cell carcinoma","volume":"374","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0078","first-page":"82014","article-title":"Mechanism based targeted therapy for hereditary leiomyomatosis and renal cell cancer (HLRCC) and sporadic papillary renal cell carcinoma: interim results from a phase 2 study of bevacizumab and erlotinib","volume":"Volume 50","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0079","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejca.2017.10.014","article-title":"Crizotinib achieves long-lasting disease control in advanced papillary renal-cell carcinoma type 1 patients with MET mutations or amplification. EORTC 90101 CREATE trial","volume":"87","author":"Sch\u00f6ffski","year":"2017","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0080","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.2017.72.2967","article-title":"Biomarker-based phase II trial of savolitinib in patients with advanced papillary renal cell cancer","volume":"35","author":"Choueiri","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0081","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1200\/JCO.2012.43.3383","article-title":"Phase II and biomarker study of the dual MET\/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma","volume":"31","author":"Choueiri","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0082","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1073\/pnas.1525735113","article-title":"Genomic characterization of sarcomatoid transformation in clear cell renal cell carcinoma","volume":"113","author":"Bi","year":"2016","journal-title":"PNAS"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0083","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00432-016-2304-3","article-title":"Presence of sarcomatoid differentiation as a prognostic indicator for survival in surgically treated metastatic renal cell carcinoma","volume":"143","author":"Gu","year":"2017","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0084","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1158\/2326-6066.CIR-15-0150","article-title":"PD-1 and PD-L1 expression in renal cell carcinoma with sarcomatoid differentiation","volume":"3","author":"Joseph","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0085","doi-asserted-by":"crossref","first-page":"6686","DOI":"10.1158\/1078-0432.CCR-17-1057","article-title":"Sarcomatoid renal cell carcinoma has a distinct molecular pathogenesis, driver mutation profile, and transcriptional landscape","volume":"23","author":"Wang","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0086","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1200\/JCO.2008.18.0000","article-title":"Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy","volume":"27","author":"Golshayan","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0087","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.eururo.2015.07.008","article-title":"Anti-programmed cell death protein 1 (PD-1) antibody nivolumab leads to a dramatic and rapid response in papillary renal cell carcinoma with sarcomatoid and rhabdoid features","volume":"68","author":"Geynisman","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0088","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.clgc.2017.05.018","article-title":"Immune check point inhibition in sarcomatoid renal cell carcinoma: a new treatment paradigm","volume":"15","year":"2017","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.urolonc.2018.10.027_bib0089","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.eururo.2016.01.051","article-title":"Genomic characterization of renal cell carcinoma with sarcomatoid dedifferentiation pinpoints recurrent genomic alterations","volume":"70","author":"Malouf","year":"2016","journal-title":"Eur Urol"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143918304368?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143918304368?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:19:44Z","timestamp":1761041984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143918304368"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":89,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S1078143918304368"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2018.10.027","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mutations in renal cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2018.10.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}